Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 2

Sponsor Class

OTHER 23NETWORK 3NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 9Lymphoma, Follicular 5Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 2Oncology Patients Receiving Chemotherapy 1Lymphoma, B-Cell 1

Interventions

Rituximab 101Cyclophosphamide 51Prednisone 32Doxorubicin 32Vincristine 31Gemcitabine 29Lenalidomide 27Oxaliplatin 22Bendamustine Hydrochloride 19ibrutinib 16fludarabine 16tafasitamab 12polatuzumab vedotin 12venetoclax 11tisagenlecleucel 11obinutuzumab 11loncastuximab tesirine 9Etoposide 9zanubrutinib 8Prednisolone 8Injections 8Ifosfamide 8Carboplatin 8selinexor 7pembrolizumab 7durvalumab 7axicabtagene ciloleucel 7Dexamethasone 7tazemetostat 6parsaclisib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Large B-Cell, Diffuse × ibritumomab tiuxetan × Clear all
NCT00322218 2022-01-19

Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

Spectrum Pharmaceuticals, Inc

Phase 3 Terminated
68 enrolled 9 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01510184 2021-12-16

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

Spectrum Pharmaceuticals, Inc

Phase 3 Terminated
79 enrolled 9 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡